新型噁唑烷酮类抗菌药:特地唑胺

A new oxazolidinone antibacterial drug: tedizolid

特地唑胺(tedizolid)是第二代噁唑烷酮类抗菌药,于2014年6月由美国食品和药物管理局(FDA)批准上市,用于成人急性细菌性皮肤及皮肤结构感染。特地唑胺不仅可以静脉输注,还可以口服给药,具有抗菌活性强、口服生物利用度高、半衰期长及给药剂量无需根据清除器官的功能或给药途径进行调整等优点,并对某些万古霉素、利奈唑胺耐药的菌株也具有很强的体外抗菌活性,是较为理想的抗菌药。

Tedizolid is a second-generation oxazolidinone antibacterial drug, approved by the U.S. FDA in June 2014, for acute bacterial skin and skin structure infections in adults. Tedizolid can not only be infused intravenously, but also be administered orally. As an ideal antibacterial drug, tedizolid has the advantages of strong antibacterial activity, high oral bioavailability, and long half-life, with dosage does not need to be adjusted according to the function of clearance organs or the route of administration, and it has strong antibacterial activity in vitro against certain vancomycin and linezolid resistant strains.